US EditionMediPharm Labs Responds to Fabricated Allegations From Dissident Shareholder - MediPharm Labs (OTC:MEDIF)
- On May 29, 2025, MediPharm Labs Corp., a Toronto-based pharmaceutical company specialized in precision cannabinoids, responded to allegations by Apollo Technology Capital Corporation.
- Apollo, owning 3% of MediPharm, issued claims of malfeasance which MediPharm describes as baseless and part of a misinformation campaign seeking board control.
- MediPharm completed its fiscal year 2025 audit with MNP LLP, receiving an unqualified audit report issued at the end of March 2025, continuing its consistent record of favorable audit outcomes since becoming a publicly traded company.
- MediPharm has initiated legal proceedings to address Apollo's alleged material misstatements and seeks court costs, emphasizing operations comply with applicable laws across multiple countries.
- The dispute highlights ongoing shareholder tensions, with Apollo's 3% ownership and campaign potentially leading to proxy contests impacting MediPharm’s board governance.
10 Articles
10 Articles
St Catharines Standard
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today confirmed that the Company is aware of the news release issued by Apollo…
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder - MediPharm Labs (OTC:MEDIF)
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE:MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today confirmed that the Company is aware of the news release issued by Apollo Technology Capital Corporation ("Apollo") on May 29, 2025 making baseless allegations of malfeasance against the Company. These patently false allegations have been inten…
Muskoka Region
Alleged Securities Fraud at MediPharm Labs Says Apollo Capital
Multiple Highly Credible Sources Reveal Disturbing Evidence of Alleged Systemic Violations of Securities Laws at MediPharm Labs; Immediate Regulatory Action Demanded
StockTalk | Cannabis Report: Inhaling and exhaling
This Canadian pharmaceutical company has made headlines again—this time for both its scientific strides with a cannabis inhaler and boardroom conflicts. A proxy battle is brewing with a dissident shareholder, raising concerns about governance and financial stability. Source: MediPharm Labs. Click here for the full story. Weekly Update – Top Cannabis News Stories 1 | Canopy Growth trims losses, eyes profit in 2026 2 | Diversify away from cannabis…
Coverage Details
Bias Distribution
- 86% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
